Tranzyme (TZYM) Halts TZP-102 Phase 2b; Cites Insufficient Efficacy

Tranzyme Pharma (Nasdaq: TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy. The decision followed a planned interim futility analysis, which examined patients' responsiveness to thrice daily oral dosing of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial. The results are consistent with the findings of a prior Phase 2b trial in that there was a very large placebo effect and no treatment effect.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Altamira Therapeutics (CYTO) Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
• Deckers Brands (DECK) Appoints Marco Ellerker as President of Global Marketplace
• Genco Shipping & Trading Limited (GNK) Sends Letter to Shareholders